Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Pain reliever may help treat life-threatening childhood disease

30.11.2004


A drug withdrawn from pharmacy shelves over 20 years ago may point the way to a new treatment for spinal muscular atrophy, or SMA, a muscle-wasting and often life-threatening childhood disease.



A new study suggests that the drug, called indoprofen, increases the production of a protein that is key to the survival of the nerve cells affected by the disease. Indoprofen was taken off the market in the early 1980s due to reports of serious gastrointestinal reactions as well as reports that the drug caused cancer in laboratory rats. Researchers are now looking into ways to modify the drug to make it less toxic to humans, said Arthur Burghes, a study co-author and a professor of molecular and cellular biochemistry at Ohio State University.

While SMA strikes only about one in 6,000 newborn Americans each year, it is the leading genetic cause of infant and toddler death in the United States as well as Western Europe. There is no cure or standard treatment, and children with the most severe form of the disease usually die before their second birthday. Motor neurons – nerve cells that send signals from the spinal cord to muscles throughout the body – rapidly deteriorate in SMA due to reduced levels of survival motor neuron (SMN) protein. Patients with the disease lack SMN1, a gene that produces SMN protein. For reasons that aren’t clear, this protein deficiency affects only motor neurons of the spinal cord – all other cells in the body function normally.


SMA patients do have one or more copies of SMN2, a gene that produces low levels of SMN protein. But these levels aren’t high enough to stop SMA’s deleterious effects on spinal motor neurons. Laboratory experiments using indoprofen to treat human fibroblast cells resulted in a 13 percent increase in SMN protein production in the cells. "This increase is sort of like giving an additional SMN2 gene to a patient – it would give the patient about 13 to 15 percent more protein," Burghes said. "While this additional protection wouldn’t cure the disease, it could lessen the severity of symptoms."

The study appears in the current issue of the journal Chemistry and Biology. Burghes worked with a team of scientists from Columbia University, the National Institutes of Health, the University of Massachusetts Medical School and a hospital in the United Kingdom. Brent Stockwell, the study’s principal investigator, is a researcher at Columbia University.

The researchers screened 47,000 chemical compounds to find ones that would boost SMN2’s protein production capabilities. Included in this group were a number of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. Out of all the compounds screened, indoprofen was the only drug – including the only NSAID – that showed an effect. Researchers used human fibroblasts taken from patients with Type I SMA, the most severe form of the disease. While SMA doesn’t harm fibroblasts, the cells still lack the SMN1 gene. "We can’t extract spinal neurons from humans, and the fibroblasts gave us a pretty good idea of indoprofen’s affect on human cells," Burghes said.

SMN protein production increased by 13 percent in the treated fibroblasts.

"Theoretically, children with less severe forms of SMA may get even more protection than this, since these children have more copies of the SMN2 gene than do children with the most severe form," Burghes said.

The researchers also tested indoprofen’s effects on mice pregnant with SMA offspring. "What is still unclear is at what point motor neurons most need the additional SMN protein," Burghes said. "Should we give treatment once a patient has symptoms, before the symptoms start, or even in utero? We just don’t know." Even so, indoprofen still gives researchers a good starting point for creating drugs to help treat SMA, he said. "The next step is to work on modifying the drug to make it an optimal compound for treating SMA, and to try to find other compounds that work in a similar way," Burghes said. "Chemical modification of indoprofen will hopefully help us create a better drug."

This work was funded by grants from Andrew’s Buddies, Families of SMA and the National Institutes of Health. Work in Burghes’ laboratory has also been supported by the Miracle for Madison fund at Ohio State.

Arthur Burghes | EurekAlert!
Further information:
http://www.osu.edu

More articles from Life Sciences:

nachricht New technique unveils 'matrix' inside tissues and tumors
29.06.2017 | University of Copenhagen The Faculty of Health and Medical Sciences

nachricht Designed proteins to treat muscular dystrophy
29.06.2017 | Universität Basel

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making Waves

Computer scientists use wave packet theory to develop realistic, detailed water wave simulations in real time. Their results will be presented at this year’s SIGGRAPH conference.

Think about the last time you were at a lake, river, or the ocean. Remember the ripples of the water, the waves crashing against the rocks, the wake following...

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Nanostructures taste the rainbow

29.06.2017 | Physics and Astronomy

New technique unveils 'matrix' inside tissues and tumors

29.06.2017 | Life Sciences

Cystic fibrosis alters the structure of mucus in airways

29.06.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>